Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 342,300 | 197,900 | 478,600 | 324,900 | 115,400 |
| Depreciation Amortization | 35,100 | 7,300 | 17,400 | 22,600 | 14,900 |
| Income taxes - deferred | -86,400 | -61,100 | 165,400 | 117,200 | -51,100 |
| Accounts receivable | -165,700 | -81,400 | -210,500 | -248,900 | -116,600 |
| Other Working Capital | -83,100 | -3,000 | -128,800 | -248,000 | -62,800 |
| Other Operating Activity | 240,000 | 86,100 | 460,600 | 426,500 | 267,000 |
| Operating Cash Flow | $282,200 | $145,800 | $782,700 | $394,300 | $166,800 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -856,900 | -560,300 | -1,319,800 | -996,800 | -588,300 |
| PPE Investments | -16,900 | -9,100 | -34,000 | -36,400 | -23,200 |
| Net Acquisitions | -2,295,300 | 63,200 | N/A | N/A | N/A |
| Sale Of Investment | 2,527,500 | N/A | 1,089,400 | 821,700 | 596,700 |
| Investing Cash Flow | $-641,600 | $-506,200 | $-264,400 | $-211,500 | $-14,800 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 600,000 | N/A | N/A | N/A | N/A |
| Debt Repayment | -600,000 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 108,400 | 23,600 | 129,400 | 92,100 | 46,500 |
| Common Stock Repurchased | -66,000 | -54,000 | -167,700 | -167,700 | -167,700 |
| Other Financing Activity | -65,100 | -55,700 | 0 | 0 | 0 |
| Financing Cash Flow | $-22,700 | $-86,100 | $-38,300 | $-75,600 | $-121,200 |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | 200 |
| Beginning Cash Position | 721,000 | 721,000 | 241,000 | 241,000 | 241,000 |
| End Cash Position | 338,900 | 274,500 | 721,000 | 348,200 | 272,000 |
| Net Cash Flow | $-382,100 | $-446,500 | $480,000 | $107,200 | $31,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 282,200 | 145,800 | 782,700 | 394,300 | 166,800 |
| Capital Expenditure | -16,900 | -9,100 | -34,000 | -36,400 | -23,200 |
| Free Cash Flow | 265,300 | 136,700 | 748,700 | 357,900 | 143,600 |